Peptide Receptor Radionuclide Therapy Prolongs Survival in Neuroendocrine Neoplasms: A Single Centre Study in 1048 Patients over 10 Years Abstract #1570

Introduction: Peptide receptor radionuclide therapy (PRRT) of somatostatin receptor (SSTR) expressing neuroendocrine neoplasms (NEN) has shown promising results about progression free survival (PFS) and overall survival (OS) in numerous phase II trials, and also in a recently published randomized controlled prospective phase III study (NETTER-1).
Aim(s): To assess the OS and PFS in NEN patients (pts) undergoing PRRT.
Materials and methods: Of the 2294 pts screened by Ga-68 SSTR PET/CT, 1048 pts received ≥1 cycle of Y-90 or Lu-177 based PRRT and were included in the intention to treat analysis. PFS determined by Ga-68 SSTR PET/CT was analyzed.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Harshad Kulkarni
Keywords: PRRT, Survival, PET/CT

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1020 Peptide Receptor Radionuclide Therapy for Progressive and Metastatic Neuroendocrine Tumors: Analysis of Efficacy in 1000 Patients from a Single Center
Introduction: Peptide receptor radionuclide therapy (PRRT) is beneficial in well-differentiated neuroendocrine tumors (NETs).
Conference: 11th Annual ENETS Conference (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Prof. Richard P Baum
Keywords: PRRT
#1827 Primary Tumor Resection Results in Superior Overall Survival after Peptide Receptor Radionuclide Therapy in Advanced Neuroendocrine Neoplasms
Introduction: Peptide receptor radionuclide therapy (PRRT) is an highly effective therapeutic option to treat advanced neuroendocrine neoplasms (NEN). However, it is still unclear whether resection of primary tumors improves overall survival (OS) after PRRT.
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: PD Dr. Daniel Kaemmerer
Keywords: PRRT, surgery
#156 Toxicity, response and survival analyses of Peptide Receptor Radionuclide Therapy (PRRT) in treatment refractory metastatic thyroid cancer using Yttrium-90 and Lutetium-177 Labeled somatostatin analogs
Introduction: Medullary thyroid carcinoma (MTC) represents about 3-16% of thyroid cancer. After first line treatment, therapeutic options for locally recurrent or metastasizing tumors include repeated surgery, whenever possible. Doxorubicin containing chemotherapy regimens in iodine-nonavid differentiated thyroid cancer have poor efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad
Authors: Prasad V, Budiawan H, Ali S, Hoersch D, ...
#1944 Predictive Value of Baseline Hematology Parameters on Outcome of 177Lu-DOTATOC PRRT
Introduction: In external beam radiotherapy it has been well established that improved tissue O2 increases therapy efficacy, likely mediated by O2 derived free radicals. Additionally, emerging evidence suggests immuno-stimulatory effects of radiotherapy through activation of lymphocytes.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Prof. Dr. Cornelis van Echteld
Authors: Kluge A, Baum R, Kulkarni H, Niepsch K, ...
#2236 Carcinoid Syndrome Open Questions – Evaluations from a Real Life Setting
Introduction: Carcinoid syndrome (CS) is frequent in patients with neuroendocrine neoplasia of the small bowel and limits quality of life and may influence prognosis compared to patients with non-functional neuroendocrine neoplasia.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Robert Fijalkowski